Cytochrome P450 26B (CYP26B1) Human shRNA Plasmid Kit (Locus ID 56603)
CAT#: TL305132
CYP26B1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 7,740.00
Product images
CNY 1,999.00
CNY 2,700.00
CNY 4,070.00
Specifications
Product Data | |
Product Name | Cytochrome P450 26B (CYP26B1) Human shRNA Plasmid Kit (Locus ID 56603) |
Locus ID | 56603 |
UniProt ID | Q9NR63 |
Synonyms | CYP26A2; P450RAI-2; P450RAI2; RHFCA |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | CYP26B1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 56603). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_001277742, NM_019885, NM_019885.1, NM_019885.2, NM_019885.3, NM_001277742.1, BC069443, BC109205 |
Summary | This gene encodes a member of the cytochrome P450 superfamily. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The encoded protein is localized to the endoplasmic reticulum, and functions as a critical regulator of all-trans retinoic acid levels by the specific inactivation of all-trans retinoic acid to hydroxylated forms. Mutations in this gene are associated with radiohumeral fusions and other skeletal and craniofacial anomalies, and increased levels of the encoded protein are associated with atherosclerotic lesions. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2013] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Documents
Product Manuals |
FAQs |
SDS |
其它CYP26B1产品